Tag Archives: Geulah Livshits

Tocagen (TOCA) Receives a Hold from Chardan Capital

In a report released today, Geulah Livshits from Chardan Capital reiterated a Hold rating on Tocagen (TOCA – Research Report), with a price target of $1.00. The company’s shares closed last Monday at $0.75, close to its 52-week low of

Chardan Capital Remains a Hold on Tocagen (TOCA)

Chardan Capital analyst Geulah Livshits maintained a Hold rating on Tocagen (TOCA – Research Report) today and set a price target of $1.00. The company’s shares closed last Monday at $0.64, close to its 52-week low of $0.53. According to

Chardan Capital Reiterates a Buy Rating on Iovance Biotherapeutics (IOVA)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) today and set a price target of $33.00. The company’s shares closed last Monday at $20.66. According to TipRanks.com, Livshits is a 2-star analyst

Moderna (MRNA) Received its Third Buy in a Row

After Roth Capital and Needham gave Moderna (NASDAQ: MRNA) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Moderna today and set a price target of

Rocket Pharmaceuticals (RCKT) Received its Third Buy in a Row

After William Blair and Cowen & Co. gave Rocket Pharmaceuticals (NASDAQ: RCKT) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits initiated coverage with a Buy rating on Rocket Pharmaceuticals today

Chardan Capital Keeps Their Buy Rating on Replimune Group Inc (REPL)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Replimune Group Inc (REPL – Research Report), with a price target of $28.00. The company’s shares closed last Monday at $14.77. According to TipRanks.com, Livshits